FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1836768312> ?p ?o ?g. }

• W1836768312 abstract "Many people with schizophrenia do not achieve a satisfactory treatment response with ordinary antipsychotic drug treatment and various additional medications are used to promote additional response. The antiepileptic carbamazepine is one such drug.To review the effects of carbamazepine and its derivatives for the treatment of schizophrenia and schizoaffective psychoses.We searched Biological Abstracts (1980-2001), The Cochrane Library (Issue 3, 2001), The Cochrane Schizophrenia Group's Register of Trials (December 2001), EMBASE (1980-2001), MEDLINE (1966-2001), PsycLIT (1886-2001) and PSYNDEX (1974-2001). Citations from included trials were also inspected and relevant companies and authors contacted for additional data.All randomised controlled trials comparing carbamazepine or compounds of the carbamazepine family to placebo or no intervention, whether as sole treatment or as an adjunct to antipsychotic medication for the treatment of schizophrenia and/or schizoaffective psychoses.Citations and, where possible, abstracts were independently inspected by reviewers, papers ordered, re-inspected and quality assessed. Data were extracted independently by at least two reviewers. Dichotomous data were analysed using Peto odds ratio (OR) and the 95% confidence interval (CI) estimated. Where possible the number needed to treat (NNT) or number needed to harm statistics were calculated.Ten studies with a total of 258 participants were included. One study comparing carbamazepine with placebo as the sole treatment for schizophrenia (n=31) was stopped early due to high relapse rate. No effect of carbamazepine was evident (OR relapse 1.5 CI 0.2 to 9.7). Another study (n=38) compared carbamazepine with antipsychotics as the sole treatment for schizophrenia. No differences in terms of mental state were found (OR 50% BPRS reduction 1.9 CI 0.5 to 7.2). More people who received the antipsychotic (perphenazine) had parkinsonism (OR 0.03 CI 0.01 to 0.1, NNH 1 CI 0.9 to 1.4). Eight studies compared adjunctive carbamazepine plus antipsychotics versus placebo plus antipsychotics. Adding carbamazepine was as acceptable as adding placebo (n=182, OR leaving the study early 0.4 CI 0.1 to 1.4). Carbamazepine augmentation of antipsychotics was superior compared with antipsychotics alone, but participant numbers were low (n=38, OR 0.1 CI 0.02 to 0.4, NNT 2 CI 1 to 5). There were no differences for mental state outcomes (6 RCTs, n=147, OR 50% BPRS reduction 0.99 CI 0.2 to 6.0). Less people in the carbamazepine augmentation group had movement disorders than those taking haloperidol alone (1 RCT, n=20, OR 0.15 CI 0.03 to 0.8). The effects of carbamazepine on subgroups of people with schizophrenia and aggressive behaviour, negative symptoms or EEG abnormalities or with schizoaffective disorder are unknown.Based on currently available evidence from randomised trials, carbamazepine cannot be recommend for routine clinical use for sole treatment, or augmentation of antipsychotic treatment, of schizophrenia. Large, simple well-designed and reported trials are justified especially if focusing on those with violent episodes and people with schizoaffective disorders or on those with both schizophrenia and EEG abnormalities." @default.
• W1836768312 created "2016-06-24" @default.
• W1836768312 creator A5002251483 @default.
• W1836768312 creator A5013031947 @default.
• W1836768312 creator A5067376573 @default.
• W1836768312 creator A5068206298 @default.
• W1836768312 date "2002-07-22" @default.
• W1836768312 modified "2023-09-24" @default.
• W1836768312 title "Carbamazepine for schizophrenia and schizoaffective psychoses" @default.
• W1836768312 cites W102345241 @default.
• W1836768312 cites W125426118 @default.
• W1836768312 cites W149080757 @default.
• W1836768312 cites W1582529222 @default.
• W1836768312 cites W1591259115 @default.
• W1836768312 cites W185701212 @default.
• W1836768312 cites W1904912651 @default.
• W1836768312 cites W1966573651 @default.
• W1836768312 cites W1966845244 @default.
• W1836768312 cites W1971924354 @default.
• W1836768312 cites W1972686340 @default.
• W1836768312 cites W1978544042 @default.
• W1836768312 cites W1981353140 @default.
• W1836768312 cites W1981453393 @default.
• W1836768312 cites W1986215651 @default.
• W1836768312 cites W1987815443 @default.
• W1836768312 cites W1992083518 @default.
• W1836768312 cites W1993007848 @default.
• W1836768312 cites W1993864023 @default.
• W1836768312 cites W1994480915 @default.
• W1836768312 cites W2002046627 @default.
• W1836768312 cites W2002181281 @default.
• W1836768312 cites W2005697734 @default.
• W1836768312 cites W2011932878 @default.
• W1836768312 cites W2017007454 @default.
• W1836768312 cites W2020844317 @default.
• W1836768312 cites W2021861716 @default.
• W1836768312 cites W2026990149 @default.
• W1836768312 cites W2027328601 @default.
• W1836768312 cites W2032312186 @default.
• W1836768312 cites W2038705111 @default.
• W1836768312 cites W2043786492 @default.
• W1836768312 cites W2054713884 @default.
• W1836768312 cites W2055025798 @default.
• W1836768312 cites W2059555288 @default.
• W1836768312 cites W2060997564 @default.
• W1836768312 cites W2064233902 @default.
• W1836768312 cites W2075769095 @default.
• W1836768312 cites W2076808235 @default.
• W1836768312 cites W2079949405 @default.
• W1836768312 cites W2081747484 @default.
• W1836768312 cites W2082523704 @default.
• W1836768312 cites W2083594899 @default.
• W1836768312 cites W2085360366 @default.
• W1836768312 cites W2087358866 @default.
• W1836768312 cites W2087857295 @default.
• W1836768312 cites W2089868642 @default.
• W1836768312 cites W2104644757 @default.
• W1836768312 cites W2105603256 @default.
• W1836768312 cites W2109775420 @default.
• W1836768312 cites W2114613490 @default.
• W1836768312 cites W2115492858 @default.
• W1836768312 cites W2115745188 @default.
• W1836768312 cites W2115828077 @default.
• W1836768312 cites W2116272889 @default.
• W1836768312 cites W2117584105 @default.
• W1836768312 cites W2133057678 @default.
• W1836768312 cites W2133602373 @default.
• W1836768312 cites W2140606211 @default.
• W1836768312 cites W2144504916 @default.
• W1836768312 cites W2150427074 @default.
• W1836768312 cites W2157823046 @default.
• W1836768312 cites W2165379748 @default.
• W1836768312 cites W2166645746 @default.
• W1836768312 cites W2301345657 @default.
• W1836768312 cites W2329708303 @default.
• W1836768312 cites W2399624761 @default.
• W1836768312 cites W2405814510 @default.
• W1836768312 cites W2408951354 @default.
• W1836768312 cites W2409310562 @default.
• W1836768312 cites W2415246766 @default.
• W1836768312 cites W2415572724 @default.
• W1836768312 cites W2419006386 @default.
• W1836768312 cites W2419225460 @default.
• W1836768312 cites W2464854342 @default.
• W1836768312 cites W2470267523 @default.
• W1836768312 cites W2724401182 @default.
• W1836768312 cites W2922475550 @default.
• W1836768312 cites W3026550232 @default.
• W1836768312 cites W4300810600 @default.
• W1836768312 doi "https://doi.org/10.1002/14651858.cd001258" @default.
• W1836768312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12137621" @default.
• W1836768312 hasPublicationYear "2002" @default.
• W1836768312 type Work @default.
• W1836768312 sameAs 1836768312 @default.
• W1836768312 citedByCount "16" @default.
• W1836768312 countsByYear W18367683122012 @default.
• W1836768312 countsByYear W18367683122014 @default.
• W1836768312 countsByYear W18367683122016 @default.
• W1836768312 crossrefType "reference-entry" @default.
• W1836768312 hasAuthorship W1836768312A5002251483 @default.

• next